Alyeska Investment Group
ATRA icon

Alyeska Investment Group’s Atara Biotherapeutics ATRA Stock Holding History

Alyeska Investment Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,356
Closed -$2.06M – 510
2020
Q3 		$2.06M Sell
6,356
-2,722
-30% -$927K 0.03% 349
2020
Q2 		$3.31M Buy
+9,078
New +$2.29M 0.05% 308
2018
Q1 		– Sell
-6,995
Closed -$3.17M – 444
2017
Q4 		$3.17M Hold
6,995
– – 0.03% 292
2017
Q3 		$2.89M Buy
6,995
+125
+2% +$47.1K 0.02% 327
2017
Q2 		$2.4M Sell
6,870
-6,447
-48% -$2.48M 0.02% 333
2017
Q1 		$6.84M Sell
13,317
-3,011
-18% -$1.25M 0.06% 281
2016
Q4 		$5.8M Buy
16,328
+130
+0.8% +$55K 0.05% 312
2016
Q3 		$8.66M Buy
+16,198
New +$8.8M 0.08% 288

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alyeska Investment Group's ATRA Position: Q4 2020 in Review

Alyeska Investment Group sold out of Atara Biotherapeutics (ATRA) in Q4 2020, closing a stake of 6,356 shares — an estimated $2.06M sold.

Alyeska Investment Group first reported a position in ATRA in Q3 2016 and held it in 8 quarters. The position peaked at $8.66M in Q3 2016. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

  • Alyeska Investment Group reported no remaining Atara Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 6,356 Atara Biotherapeutics shares in Q4 2020, an estimated $2.06M.
  • Alyeska Investment Group first reported a position in Atara Biotherapeutics in Q3 2016 and held it in 8 quarters.
  • Alyeska Investment Group's Atara Biotherapeutics position peaked at $8.66M in Q3 2016.
  • 148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on Alyeska Investment Group's 13F filing for Q4 2020, filed 16 Feb 2021.